



## **Antiretroviral Therapy and Statin Drug Interactions**

**Date:** 7/28/2020 **Time:** 12:00 – 1:00 PM

Continuing Professional Education Program Clinical Pharmacy Associates, Inc. & DC Department of Health HIV/AIDS, Hepatitis, STD, TD Administration

<u>Who should attend</u>: The program is designed for pharmacists in the DC HIV/AIDS Pharmacy Network and pharmacists in client organizations of CPA/MedNovations.

<u>Needs Statement</u>: Emerging antiretroviral drug development for treatment of persons living with HIV (PLWH)includes new injectable drugs and formulations. The injectable route of administration of antiretrovirals, first occurring with the FDA- approved drug ibalizumab, represents both opportunities and challenges for accessible, safe and efficacious use of treatment in clinical practice. Pharmacy professionals must be knowledgeable and provide essential pharmaceutical services to optimize injectable antiretrovirals in the community and organized health care settings.

Statement of Goal: To equip the practicing pharmacist professional with current knowledge regarding the drugs, role/s, use and operational considerations to employ injectable ARVs in the care of PLWH.

**Activity Type:** Knowledge

**Objectives:** After completing the program, participants should be able to:

- Discuss the epidemiology of cardiovascular disease and risk factors in patients with HIV
- Explain the effects of HIV and anti-retroviral drugs on the lipid profile
- Review the management of cardiovascular risk with statins
- Identify the various drug-interactions that can occur with statin-ART drug combinations and how to manage them

## **Faculty**

Bamidele Kalejaiye, PharmD, BCPS, AAHIVP, RPh Associate/Clinical Pharmacist Clinical Pharmacy Associates, Inc. 301-617-0555

® Howard University College of Pharmacy, (COP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of Continuing Professional Education. **This program meets ACPE criteria for one hour (0.10 CEU).** Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program. Using the following URL: <a href="https://hurxce.learningexpressce.com/index.cfm">https://hurxce.learningexpressce.com/index.cfm</a>, the evaluation form and a score ≥ 70% correct on post-test questions will be required for successful completion. The ACPE Universal Program number assigned to this

program is: 0010-9999-20-031-L02-P. CE deadline is 09/22/2020